R&D pipeline: balanced with focus
Research and development programmes continue to progress year by year with a strong focus in four key areas: respiratory, neonatology, rare disease and special care.
Parma, Italy and Solna, Sweden, March 7, 2023 - Chiesi Farmaceutici S.p.A (Chiesi Group) and Affibody AB (Affibody) today announced the signing of a collaboration and global license agreement for the development and commercialization of innovative treatments for respiratory diseases using Affibody's proprietary technology.
The agreement provides for the close collaboration of the parties, to carry out up to three programs based on Affibody® molecules in favor of specific targets for respiratory diseases. Chiesi will finance the research, development and subsequent marketing of its products worldwide, in line with the strategy and commitment to provide the best level of assistance to people affected by respiratory diseases, going beyond treatments and focusing on patient experience. Affibody has maintained the co-promotion option in the Nordic countries.
"Chiesi has always been committed to the research and development of new innovative treatments in the field of respiratory diseases, an area that represents a strategic priority for our organization. The collaboration with Affibody adds to our research and development portfolio a new important modality characterized by technological properties that make possible the inhalation route of administration of mini-proteins, thus allowing us to develop new treatments for people with unmet clinical needs”, commented Thomas Eichholtz, Head of Global R&D of the Chiesi Group.
|
Trade Name |
Active Principle |
Code |
Formulation |
Phase ❋ 1 2 3 4 |
Indication / Disease |
Alliance / Partnership |
|---|
Explore our Pipeline
Action Areas